

INFORME DE SEGURIDAD

DIRECCIÓN DE DISPOSITIVOS MÉDICOS Y OTRAS TECNOLOGÍAS

ANEXO

www.ecri.org . Printed from Health Devices Alerts on Tuesday, June 27, 2017 Page 1

[High Priority] - A28365 : Carl Zeiss—Uninterruptible Power Supply Used with VisuMax Systems: Battery Test Circuit Components May Combust Medical Device Ongoing Action

Published: Monday, June 12, 2017
Last Updated: Tuesday, June 27, 2017

UMDNS Terms:

- Lasers, Yb:YAG [31525]
- Power Supplies [18557]

Product Identifier:

Uninterruptible Power Supplies (UPSs) used with VisuMax Systems [Capital Equipment]
Serial Nos.: 963599 through 1157772 (not including those with a previously replaced UPS)

Geographic Regions: Worldwide

Manufacturer(s): Carl Zeiss Meditec AGGoeschwitzer Strasse 51-52, D-07745 Jena, Germany

Suggested Distribution: Clinical/Biomedical Engineering, OR/Surgery, Ophthalmology

Problem:

In a January 23, 2017, Field Corrective Action letter posted by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and a March 17, 2017, Field Corrective Action letter posted by the German Federal Institute for Drugs and Medical Devices (BfArM), Carl Zeiss states that the battery test circuit components of the above systems may fail, potentially leading to combustion of device components. Carl Zeiss also states that the probability of a serious injury occurring in association with this problem is extremely unlikely because of a fire enclosure and other risk control measures; however, smoke intoxication may occur as a result of the components generating smoke and a burning smell during combustion. Additionally, Carl Zeiss states that newly manufactured UPS modules do not pose this risk because they have an updated design preventing the problem.

Action Needed:

Identify any affected product in your inventory. If you have affected product, verify that you have received either the January 23, 2017, and/or the March 17, 2017, Field Corrective Action letter(s) and feedback sheet from Carl Zeiss. Complete the feedback sheet, and return it to Carl Zeiss by email at: fca-jen.med.de@zeiss.com. Carl Zeiss refractive support team will contact your facility with additional information regarding the handling of this Field Corrective Action.

For Further Information:

Carl Zeiss
Website: [Click here](#)

References:

- Great Britain. Medicines and Healthcare Products Regulatory Agency. VisuMax with treatment-pack and accessories [online]. London: Department of Health; 2017 May 2 [cited 2017 Jun 7]. (Field safety notice; reference no. 2017/004/025/299/027). Available from Internet: [here](#).
- Germany. Federal Institute for Drugs and Medical Devices. Urgent field safety notice for VisuMax, Carl Zeiss Meditec AG [online]. 2017 Apr 4 [cited 2017 Jun 7]. Available from Internet: [Click here](#).

Comments:

- This alert is a living document and may be updated when ECRI Institute receives additional information. In circumstances in which we determine that it is appropriate for customers to repeat their review of an issue (e.g., when additional affected product has been identified), we will post a separate update alert. In other cases, we may add information, such as additional commentary, recommendations, and/or source documents, to the original alert. For additional information regarding the format of this alert, refer to our [HDA Format Guide](#).

Source(s):

- 2017 Jun 7. MHRA FSN. 2017/004/025/299/027 [Download](#)
- 2017 Jun 7. MHRA FSN. Carl Zeiss reference no. 3485 [Download](#)
- 2017 Jun 7. BfArM (Germany). 00737/17 [Download](#)
- 2017 Jun 7. BfArM (Germany). Carl Zeiss reference no. 3485 [Download](#)
- 2017 Jun 27. Manufacturer. The manufacturer confirmed the information in the source material.